Letrozole and Aranesp drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Letrozole (letrozole) and Aranesp (darbepoetin alfa). Common drug interactions include weight decreased among females and adenoma benign among males.

The phase IV clinical study analyzes what interactions people have when they take Letrozole and Aranesp. It is created by eHealthMe based on reports of 93 people who take the same drugs from the FDA, and is updated regularly.

What is Letrozole?

Letrozole has active ingredients of letrozole. It is often used in breast cancer. eHealthMe is studying from 54,125 Letrozole users. Check the latest studies of Letrozole.

What is Aranesp?

Aranesp has active ingredients of darbepoetin alfa. It is often used in anemia. eHealthMe is studying from 54,331 Aranesp users. Check the latest studies of Aranesp.



On Jul, 09, 2026

93 people who take Letrozole and Aranesp together, and have interactions are studied.

Letrozole and Aranesp drug interactions.

What are the common drug interactions of Letrozole and Aranesp, by gender? *:

female:

  1. Weight decreased
  2. Death
  3. Bone disorder
  4. Hypoaesthesia (reduced sense of touch or sensation)
  5. Decreased appetite
  6. Nausea (feeling of having an urge to vomit)
  7. Erythema (redness of the skin)
  8. Neck pain
  9. Back pain
  10. Osteonecrosis of jaw (death of bone of jaw)

male:

  1. Adenoma benign (non-cancerous tumour -secreting)
  2. Anaemia (lack of blood)
  3. Bone disorder
  4. Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries)
  5. Bone loss
  6. Brain cancer metastatic
  7. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  8. Bundle branch block left (absence of transmission of electric impulses from the atrioventricular (av) bundle of his to the left ventricle)
  9. Cardiac disorder
  10. Cardiotoxicity (damage to the heart muscle)

What are the common drug interactions of Letrozole and Aranesp, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Abdominal pain lower
  2. Abscess jaw (tooth abscess or root abscess)
  3. Actinomycosis (infection that causes sores, or abscesses)
  4. Anxiety
  5. Aortic arteriosclerosis (hardening of the aortic arteries)
  6. Asthenia (weakness)
  7. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  8. Back pain
  9. Bladder cancer
  10. Bone disorder

20-29:

n/a

30-39:

  1. Anaemia (lack of blood)
  2. Breast cancer female
  3. Intervertebral disc protrusion (spinal disc protrusion)
  4. Osteopenia (a condition where bone mineral density is lower than normal)
  5. Ovarian cyst (fluid filled sac of the ovary)
  6. Acne (skin problems that cause pimples)
  7. Alopecia (absence of hair from areas of the body)
  8. Conjunctivitis (pink eye)
  9. Erythema of eyelid (redness of the eyelid)
  10. Eyelid oedema (eyelids are swollen and contain excessive fluid)

40-49:

n/a

50-59:

  1. Anxiety
  2. Arteriosclerosis (thickening and hardening of arteries)
  3. Arthralgia (joint pain)
  4. Arthropathy
  5. Asthenia (weakness)
  6. Back pain
  7. Bone density decreased
  8. Bone disorder
  9. Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries)
  10. Bone neoplasm malignant (cancer of bone)

60+:

  1. Weight decreased
  2. Anaemia (lack of blood)
  3. Fall
  4. Memory impairment
  5. Swelling
  6. Hypoaesthesia (reduced sense of touch or sensation)
  7. Night sweats (sweating in night)
  8. Urinary tract infection
  9. Dizziness
  10. Abscess jaw (tooth abscess or root abscess)

What are the existing conditions these people have? *

  1. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 28 people, 30.11%
  2. Anaemia (lack of blood): 28 people, 30.11%
  3. Pain: 16 people, 17.20%
  4. Nausea (feeling of having an urge to vomit): 16 people, 17.20%
  5. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 14 people, 15.05%
  6. Vitiligo (pigment is lost from areas of the skin): 12 people, 12.90%
  7. Stress And Anxiety: 12 people, 12.90%
  8. Metastases To Bone (cancer spreads to bone): 12 people, 12.90%
  9. Gout (uric acid crystals building up in the body): 12 people, 12.90%
  10. Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 12 people, 12.90%

* Approximation only. Some reports may have incomplete information.

Do you take Letrozole and Aranesp?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Letrozole and Aranesp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Letrozole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Aranesp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Letrozole and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Aranesp and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on letrozole and darbepoetin alfa (the active ingredients of Letrozole and Aranesp, respectively), and Letrozole and Aranesp (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: